Ethinylestradiol/norgestimate oral
Alternative Names: Norgestimate/ethinyl estradiol; Ortho Tri-Cyclen; Ortho Tri-Cyclen Lo; Ortho-Prefest; PrefestLatest Information Update: 24 Oct 2021
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development; Ortho-McNeil Pharmaceutical
- Developer Janssen Research & Development; Ortho-McNeil Pharmaceutical
- Class Alkylated estrogenic steroids; Oral contraceptives
- Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Menopausal syndrome; Pregnancy
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Pregnancy (Prevention) (In volunteers) in Netherlands (PO, Tablet)
- 01 Sep 2014 Janssen Research & Development completes a phase I trial in Contraception (In volunteers) in Netherlands (NCT02127593)
- 13 May 2014 Janssen Research & Development plan a phase I bioequivalence trial in healthy women in Netherlands (NCT02127593)